ZFIN Image: Dahlén et al., 2021, Figure 7

Image

Figure Caption

Figure 7

Potential mechanisms underlying the associations between Cannabis consumption and risks of psychosis/schizophrenia-like symptoms, with the current study’s pharmacological approaches. Δ9-tetrahydrocannabinol (THC) reduces N-methyl-D-aspartate (NMDA) release via NMDA receptor antagonism. THC also inhibits γ‐aminobutyric acid (GABA) release from interneurons in the prefrontal cortex, potentiating dopamine release. Both NMDA receptor hypoactivity and heightened dopaminergic signaling are hallmarks of schizophrenia. Pentylenetetrazol (PTZ).

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci. Rep.